Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health reported significant growth in Q2 2020, with Mytesi net sales reaching approximately $3.2 million, up 186% from Q2 2019. Gross sales were about $6.3 million, marking a 268% increase year-over-year. The company also reported a 45% reduction in net loss to $9.2 million, driven by higher Mytesi prices and decreased operating losses. Expenses fell 6% year-over-year. Total Mytesi bottles sold rose 104.3% compared to the same period last year. Despite these gains, the company continues to navigate operating losses.
Jaguar Health (NASDAQ:JAGX) announced plans to file its Q2 2020 10-Q on August 13, 2020. The company will host a conference call the same day at 8:30 a.m. ET to discuss financial results and updates. Investors can participate via a toll-free number or a live webcast on the company's website. Additionally, a virtual disease awareness event, Diarrhea Dialogues, is scheduled for October 20, 2020, focusing on cancer therapy-related diarrhea, featuring expert discussions on supportive care. Further details will be shared closer to the event date.
Jaguar Health, Inc. (NASDAQ:JAGX) will hold a conference call on August 13, 2020, at 8:30 a.m. ET to discuss Q2 2020 financials.
The company is also planning a virtual disease awareness event titled Diarrhea Dialogues on October 20, 2020, focusing on cancer therapy-related diarrhea, featuring leading oncologists and patient advocates. For more details on the investor call and event registration, visit the company's website.